Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 17/20 | 0.58 |
| ▸ | GIPR | P48546 | 3/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2667041 | 0.89 | GCGR (0.57) | GCGRGIPRCYP3A4CYP2C8CYP2C9 | |
| SCHEMBL2667079 | 0.89 | GCGR (0.57) | GCGRGIPRCYP3A4CYP2C8CYP2C9 | |
| SCHEMBL2666920 | 0.87 | GCGR (0.54) | GCGRGIPRCYP3A4CYP2C8CYP2C9 | |
| SCHEMBL5093232 | 0.85 | AURKA (0.49) | GCGRGIPRTRPV1 | |
| SCHEMBL2666892 | 0.85 | GCGR (0.58) | GCGRGIPRCYP3A4CYP2C8CYP2C9 | |
| SCHEMBL2657383 | 0.85 | GCGR (0.52) | GCGRGIPRCYP3A4CYP2C8CYP2C9 | |
| SCHEMBL5089993 | 0.83 | CCR6 (0.53) | GCGRCYP3A4CYP2C9TRPV1 | |
| SCHEMBL2660714 | 0.83 | GCGR (0.51) | GCGRGIPRCYP3A4CYP2C8CYP2C9 | |
| SCHEMBL2667070 | 0.83 | GCGR (0.54) | GCGRGIPRCYP3A4CYP2C8CYP2C9 | |
| SCHEMBL5093155 | 0.82 | TRPV1 (0.59) | GCGRGIPRCYP3A4CYP2C8CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318760-B2 | Type 2 diabetes, atherosclerosis; compounds are N-(2-carboxyethyl)benzamides or N-tetrazolyl derivatives of benzamides; glucagon antagonists | MERCK SHARP & DOHME CORP. (US) | 2012-11-27 | — | — | US | disclosed |
| US-20080161347-A1 | Substituted Aryl and Heteroaryl Derivatives, Compositions Containing Such Compounds and Methods of Use | MERCK & CO., INC. (US) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161347-A1 | Substituted Aryl and Heteroaryl Derivatives, Compositions Containing Such Compounds and Methods of Use | GPR119, PNLIP, SLC5A2 | GCGR 81/4885GIPR 124/4885CYP3A4 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.